h
haloperidol
Chemical compound
Also known as Haloperidolum · Haldol® · MCN-JR-1625 · R-1625 · Serenace® · gamma-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone
- Formula
- C₂₁H₂₃ClFNO₂
1
- C₂₁H₂₃ClFNO₂
- Mass
- 375.1401 Da
1
- 375.1401 Da
Overview
Chemistry
All data
332 statements · 77% with external sources · numbers in brackets are citations
- Significant drug interaction
Show 52 moreShow less
- cisapride
- (RS)-citalopram
- clarithromycin
- cocaine
- disopyramide
- dofetilide
- domperidone
- dronedarone
- droperidol
- erythromycin
- escitalopram
- flecainide
- halofantrine
- ibutilide
- mesoridazine
- (RS)-methadone
- moxifloxacin
- ondansetron
- pentamidine
- pimozide
- probucol
- procainamide
- quinidine
- sevoflurane
- sotalol
- sparfloxacin
- (RS)-sulpiride
- terfenadine
- thioridazine
- amiodarone side effect: long QT syndrome
- disopyramide side effect: long QT syndrome
- erythromycin side effect: long QT syndrome
- chlorpromazine side effect: long QT syndrome
- risperidone side effect: long QT syndrome
- ondansetron side effect: long QT syndrome
- clomipramine side effect: long QT syndrome
- apomorphine side effect: long QT syndrome
- pimozide side effect: long QT syndrome
- anagrelide side effect: long QT syndrome
- moxifloxacin side effect: long QT syndrome
- dronedarone side effect: long QT syndrome
- crizotinib side effect: long QT syndrome
- zuclopenthixol side effect: long QT syndrome
- pasireotide side effect: long QT syndrome
- paliperidone side effect: long QT syndrome
- (RS)-hydroxyzine side effect: long QT syndrome
- (RS)-citalopram side effect: long QT syndrome
- (RS)-sulpiride side effect: long QT syndrome
- (RS)-methadone side effect: long QT syndrome
- vandetanib side effect: long QT syndrome
- clarithromycin side effect: long QT syndrome
- droperidol side effect: long QT syndrome
- Medical condition treated
- schizophreniform disorder
1
- Tourette syndrome
1
- vomiting
1
- schizophrenia
1
- psychosis
1
Sources- 1.Stated in Drug Indications Extracted from FAERSRetrieved 2018-10-02
- schizoaffective disorder
1
Sources- 1.Stated in Drug Indications Extracted from FAERSRetrieved 2018-10-02
- mental disorder
1
Sources- 1.Stated in Drug Indications Extracted from FAERSRetrieved 2018-10-02
- anxiety
1
Sources- 1.Stated in Drug Indications Extracted from FAERSRetrieved 2018-10-02
Show 1 moreShow less
- schizophreniform disorder
- Canonical SMILES
- C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1
- C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
- Subject has role
- dopamine antagonist
2
Sources- 1.Stated in NDF-RTRetrieved 2018-03-05
- 2.Stated in Medical Subject HeadingsRetrieved 2018-03-15
- antipsychotics
1
- antiemetic
1
- anti-dyskinesia agents
1
- female reproductive toxicant(since 1999)
1
Sources- 1.Stated in California Proposition 65 list of chemicalsoehha.ca.gov/chemicals/haloperidolRetrieved 2020-02-26
- developmental toxicant(since 1999)
1
Sources- 1.Stated in California Proposition 65 list of chemicalsoehha.ca.gov/chemicals/haloperidolRetrieved 2020-02-26
- WHO essential medicines
- dopamine antagonist
- MCN code
- 2933.39.15
- Physically interacts with
- 5-hydroxytryptamine receptor 1A subject has role: antagonist
1
- 5-hydroxytryptamine receptor 1D subject has role: antagonist
1
- 5-hydroxytryptamine receptor 2A subject has role: antagonist
2
Sources- 1.Stated in IUPHAR/BPS Guide to PHARMACOLOGYRetrieved 2016-08-17
- 2.Stated in Open Targets Platformplatform.opentargets.org/drug/CHEMBL54Retrieved 2023-08-14
- 5-hydroxytryptamine receptor 2B subject has role: antagonist
1
- 5-hydroxytryptamine (serotonin) receptor 7 subject has role: antagonist
1
- 5-hydroxytryptamine receptor 7 subject has role: antagonist
1
- Dopamine receptor D1 subject has role: antagonist
1
- Dopamine receptor D2 subject has role: antagonist
1
Show 8 moreShow less
- Dopamine receptor D3 subject has role: antagonist
1
- Dopamine receptor D4 subject has role: antagonist
1
- Dopamine receptor D5 subject has role: antagonist
1
- Histamine receptor H1 subject has role: antagonist
1
- Potassium inwardly-rectifying channel, subfamily J, member 6 subject has role: antagonist
1
- Potassium voltage-gated channel subfamily H member 1 subject has role: antagonist
1
- Dopamine receptor D4 subject has role: inverse agonist
1
Sources- 1.Stated in Open Targets Platformplatform.opentargets.org/drug/CHEMBL54Retrieved 2023-08-14
- Dopamine receptor D3 subject has role: inverse agonist
1
Sources- 1.Stated in Open Targets Platformplatform.opentargets.org/drug/CHEMBL54Retrieved 2023-08-14
- 5-hydroxytryptamine receptor 1A subject has role: antagonist
- Part of
- response to haloperidol subject has role: reactant
1
- cellular response to haloperidol subject has role: reactant
1
- response to haloperidol subject has role: reactant
- LiverTox likelihood score
- LiverTox toxicity likelihood category B
1
Sources- 1.Stated in LiverToxncbi.nlm.nih.gov/books/n/livertox/HaloperidolRetrieved 2021-04-08
- LiverTox toxicity likelihood category B
- Defined daily dose
- 8 milligram route of administration: oral administration
- 8 milligram route of administration: parenteral route of administration
- 3.3 milligram route of administration: parenteral route of administration
- Legal status (medicine)
- boxed warning
1
Sources- 1.“FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.”nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802
- boxed warning
On other databases
57 identifiers linking haloperidol across the web's reference databases
- ATC codeN05AD01
- CA PROP 65 IDhaloperidol
- CAS Registry Number52-86-8
- ChEBI ID5613
- ChEMBL IDCHEMBL54
- ChemSpider ID3438
- DrugBank IDDB00502
- DrugCentral ID1353
- DSSTOX compound identifierDTXCID2014150
- DSSTox substance IDDTXSID4034150
- EC number200-155-6
- ECHA Substance Infocard ID100.000.142
- Electronic Essential Medicines List medicine ID25
- Elhuyar ZTH ID024912
- Encyclopædia Britannica Online IDscience/haloperidol
- Freebase ID/m/0199v_
- Gran Enciclopèdia Catalana IDhaloperidol
- Gran Enciclopèdia Catalana ID (former scheme)0113487
- Guide to Pharmacology Ligand ID86
- HSDB ID3093
- Human Metabolome Database IDHMDB0014645
- InChIInChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
- InChIKeyLNEPOXFFQSENCJ-UHFFFAOYSA-N
- Interlingual Index IDi54576
- J-GLOBAL ID200907040481182796
- KEGG IDC01814
- LiverTox IDHaloperidol
- MassBank accession IDMSBNK-Athens_Univ-AU112201
- MedlinePlus drug identifiera682180
- MeSH concept IDM0009771
- MeSH descriptor IDD006220
- MeSH tree codeD02.522.352.506
- Microsoft Academic ID (discontinued)2780948584
- NALT ID10297
- NCI Drug Dictionary IDhaloperidol
- NDF-RT IDN0000146461
- Nikkaji IDJ1.365J
- NMRShiftDB structure ID20207509
- NSC number170973
- OpenAlex IDC2780948584
- PDB ligand IDGMJ
- Probes And Drugs IDPD002312
- PubChem CID3559
- Quora topic IDHaloperidol
- Reaxys registry number331267
- RxNorm CUI5093
- ScienceDirect topic IDbiochemistry-genetics-and-molecular-biology/haloperidol
- SPLASHsplash10-00or-0409000000-d542c35143556b83b87a
- Store medisinske leksikon IDhaloperidol
- SureChEMBL ID8264
- UK Parliament thesaurus ID540051
- UMLS CUIC0018546
- UniChem compound ID595399
- UNIIJ6292F8L3D
- WikiProjectMed IDHaloperidol
- WordNet 3.1 Synset ID03485269-n
- World Health Organisation international non-proprietary name numeric ID918